This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for September 15th
by Zacks Equity Research
ARCE, NSSC, PAGP, TRIL, and VALE have been added to the Zacks Rank #5 (Strong Sell) List on September 15, 2021.
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion
by Zacks Equity Research
Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Company News for Aug 24, 2021
by Zacks Equity Research
Companies In The News Are: GM, JD, PFE, TRIL, MSGE.
Implied Volatility Surging for Trillium (TRIL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
Trillium Therapeutics (TRIL) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Trillium Therapeutics (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Trillium (TRIL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
Trillium (TRIL) Soars: Stock Adds 6% in Session
by Zacks Equity Research
Trillium (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
New Strong Sell Stocks for August 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Is the Options Market Predicting a Spike in Trillium Therapeutics (TRIL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Trillium Therapeutics (TRIL) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Trillium (TRIL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
Implied Volatility Surging for Trillium (TRIL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
4 Cheap Stocks to Buy on Signs of Coronavirus Slowdown
by Shuvra Shankar Dey
The highly oversold market offers some ultra-cheap stocks with stellar prospects as the coronavirus pandemic shows signs of slowing down.
Demand for Essential Goods Rises Amid Coronavirus: 3 Winners
by Zacks Equity Research
Despite the lagging markets, companies that offer pharmaceuticals and FMCG products have witnessed a surge in recent weeks, largely driven by strong demand for their goods.
Increased Earnings Estimates Seen for Trillium (TRIL): Can It Move Higher?
by Zacks Equity Research
Trillium (TRIL) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Is Trillium Therapeutics (TRIL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TRIL) Outperforming Other Medical Stocks This Year?
Trillium Therapeutics Inc. (TRIL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Trillium Therapeutics Inc. (TRIL).
The Wining Sector & Its Top Stocks in Virus-Infected January
by Sanghamitra Saha
January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.
Is the Options Market Predicting a Spike in Trillium (TRIL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales
by Zacks Equity Research
Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.